Thomas Soloway, T-knife CEO

What hap­pens when you give a mouse a hu­man self-anti­gen? In­vestors bet $110M to find out

T-knife Ther­a­peu­tics launched last Au­gust on a mis­sion to iso­late T cell re­cep­tors not from hu­man donors, but from mice. Now, with a new CEO and a can­di­date bound for the clin­ic, the Ver­sant-backed com­pa­ny is re­load­ing with a fresh $110 mil­lion.

“What we are try­ing to do for the field of TCR ther­a­py and sol­id tu­mor ther­a­py is very anal­o­gous to what the murine plat­forms have done in an­ti­body de­vel­op­ment,” CEO Thomas Soloway told End­points News. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.